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Beeson evokes memories of Yale
With all due respect to the “Iron
’Terns” and their considerable accomplishments [“Six
Degrees of Paul Beeson,” Yale
Medicine, Spring 2015], Paul
Beeson, M.D., attracted and
inspired many outstanding
classes of house officers during
his 13-year tenure as chairman
(pardon the old designation)
of the Department of Medicine
at Yale. He was aided in this
task by an outstanding faculty:
Gerald Klatskin, M.D., in liver
diseases, Philip Bondy, M.D., in
endocrinology, Stuart Finch,
M.D., in hematology, Howard
Spiro, M.D., in gastroenterology, Allan Goodyear, M.D., in
cardiology, and Elisha Atkins,
M.D., his partner in the study of
fever, just to name a few. I was
privileged to meet Dr. Beeson
when I was but an intern in
surgery at Yale in the 1953-54
academic year. I had recently
returned from a brief convalescence in Florida following a

nine-week hospitalization for
what was known then as serum
hepatitis contracted from a
needle stick. Dr. Beeson was
facing an abdominal operation
and, thinking ahead, wondered
whether convalescing in Florida
was a good idea, and he asked
me! I didn’t think he knew I
even existed, let alone that I
had been ill. Our very pleasant
professional and even personal
relationship continued through
my residency in surgery and
my years on the faculty before
I moved to Stanford in March
1965 at the invitation of Bob
Chase. Dr. Beeson was planning
a sabbatical year at Stanford
to begin in July 1965, and I
was doing a little house and
school searching for him and
his family. In May of that year,
I received a letter from Dr.
Beeson saying that he would
not be coming to Stanford
because he had accepted the
offer to become Nuffield Chair
of Medicine at Oxford—as

S E C ON D O PI N I ON
BY S I D N E Y H A R R I S

understandable a reason as
one could imagine for such a
change in plans.
Paul Beeson was a towering
figure in medicine, at once highly
accomplished, quietly stimulating, approachable, and modest.
Maybe someone has constructed
a family tree of his trainees
similar to the “Iron ’Terns.” If
not, someone should. That might
even be a suitable project for a
Yale School of Medicine thesis or
a talk at a meeting of the Yale
Historical Society.
James B. D. Mark, M.D., HS ’54
Professor of Cardiothoracic
Surgery, Emeritus
Stanford University School of
Medicine
Having fond memories of Paul
Beeson, M.D., upon receiving
the recent Yale Medicine, I open
immediately to the double-page
photograph of the Iron ’Terns.
Imagine my surprise and delight
in seeing myself 50 years
younger in the group. I’m the
funny-looking guy with glasses
standing in the front row,
second from the right—between
John Burke (#14) and Harold
Federman (#15). I was an assistant resident, having graduated
from Yale School of Medicine in
1963, and having been an intern
in 1963-64. For the record,
while not as academically distinguished as many of my fellow
interns, I subsequently was in
the private practice of internal
medicine for 30 years in a small
Vermont city, served as president of the medical staff at the
Rutland Regional Medical Center,
and was a clinical instructor
in medicine at the University
of Vermont.
David F. Cross, M.D. ’63, HS ’64
Glade Hill, Va.
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dialogue

		 Memory has a
role in almost every
biological process
that our memories make us who we are. We turn
our memories into stories with meaning and wisdom, and share them
in the hope that others can learn from them. Our memories take
different forms—some fleeting and others hardwired into our brains,
available for quick recall. Our immune system remembers foreign
invaders in order to stop them before they do damage, and our cells
remember whether their DNA has suffered damage and undergone
repairs. Yale Medicine spoke with Dean Robert J. Alpern, M.D., about
the importance of memory in medicine, science, and beyond.
IT H AS BEEN SA ID

Why is the study of memory so important? The study of memory is important because
of its role in almost every biological process. We think of the brain as the location of
memory, but almost every cellular and molecular process in the body uses memory
to increase its efficiency. However, understanding memory in the brain is uniquely
important because this form of memory defines who we are. We now live in an age
where we survive cancer and heart disease, but later many become impaired by diseases such as Alzheimer’s.
How will Yale’s new Alzheimer’s Disease Research Unit advance the study of disease
and, hopefully, lead to better diagnosis and treatment? When we performed strategic planning 10 years ago, one of the highest research priorities identified was
neurodegenerative diseases, and in response the Center for Cellular Neuroscience,
Neurodegeneration and Repair (CNNR) was formed. The success of CNNR contributed
to our ability to become an Alzheimer’s unit. We still don’t completely understand
what causes amyloid protein or tau to accumulate in the brain, but we hope to use the
Alzheimer’s Disease Research Unit to advance our understanding and develop new
therapies to address this disease.

F R A N K R A M S P O T T I L L U S T R AT I O N

What aspect of memory do you find most interesting? The ability of the brain to create its
own memory. People have memories that actually never happened or may not have
happened exactly as remembered. If you tell a story enough times, it starts to become
a true memory, triggering all of the biological mechanisms associated with long-term
memory. This fascinates me.
What should readers remember from this issue of Yale Medicine? They should remember
the beauty of biology. While simple memory occurs in the simplest of organisms, the
complex memory performed by our brains required a long time to evolve and defines
the human species and other high-level species. To preserve these memories is one of
the goals of medical research.

Autumn 2015
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Team-based science is focus
of new clinician scholars program
W H E N T H E RO B E R T WO O D JO H N S O N F O U N DAT I O N

(RWJF) ended its longstanding Clinical Scholars program
last year, it was a loss not only for the Yale community
but for the city of New Haven as well. Since the program’s inception more than 40 years ago, scholars have
worked on projects designed to address health inequities
and improve health care throughout the city. The more
than 160 Yale scholars who have graduated from the program since 1974 have had a strong impact on New Haven
through community-based research that assessed a range
of topics, including the availability of healthy foods in
a New Haven neighborhood without a supermarket,
HIV/AIDS status, gun violence, immigrant and refugee
health, and access to health care for the homeless.

Cary Gross has led the
transition to a new clinician scholars program,
which for the first time
teams residents with
students from the School
of Nursing.
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“I’ve never been part of a training
program that is blessed with so
much loyalty, appreciation, and
dedication among the alumni, the
faculty, and the institutional and
community partners,” said Cary
P. Gross, M.D., professor of medicine and co-director of the RWJF
program at Yale. “That is why we
simply had to find a way to continue training the next generation of scholars who will lead our
efforts to improve the health care
system and enhance the health of

individual patients, our communities, and the nation.”
Though RWJF decided last
year to stop funding the clinical scholars program, the four
host sites—the University of
California, Los Angeles; the
University of Michigan; the
University of Pennsylvania;

HAROLD SHAPIRO PHOTO

which trained physicians from
various specialties together,
including internists, surgeons,
pediatricians, and others.
“No profession can do it all
themselves, and we each have
and Yale—took up the mantle to
begin a new independent fellow- important roles to play in the
delivery of health care across the
ship in a spirit similar to that of
health continuum,” said Margaret
the original program.
Grey, Dr.P.H., M.S.W. ’76, dean
“Forging ahead was an
of the Yale School of Nursing.
unspoken mandate,” said Gross,
as the four sites decided that the “The more we educate people in
silos—whether for clinical pracwork of the program is not yet
tice, or clinical research, or health
complete. “When we discussed
services research—the less likely
the challenge with leadership
it is that they will work colat Yale, the question was never
laboratively when they get out
whether to continue trainin the real world.” In addition,
ing scholars; it was how to do
she noted, postdoctoral training
it. Dean [Robert J.] Alpern has
slots for nurses are limited, and
been incredibly supportive.” The
the NCSP will provide a muchnew National Clinician Scholars
Program (NCSP) will share many needed avenue for nurses who
seek to combine clinical work
features with the original prowith research.
gram, but the consortium made
The new two-year program
key changes in order to adapt
will select approximately five
to a new element of the changphysician- and nurse-scholars
ing health care landscape—an
per year to complete coursework
increased emphasis on teamtogether at Yale, sharing menbased approaches to research as
tors from across the professions.
well as clinical care. As a result,
NCSP scholars will lead their
the NCSP will train doctoralown policy-relevant research
level nurse-scientists side by
projects, guided by faculty and
side with physicians.
community partners. They will
In clinical practice, such
also learn the value of collaborateam-based approaches as
tion as they participate as team
patient-centered medical homes
members in their peers’ projects.
are increasingly common, and
Scholars will be encouraged
they bring together physicians,
to translate their research disnurses, physician associates,
coveries into real-world change
and others to collaborate with
by working with community
patients in making decisions
partners, health care providers,
about care. “Team-based care
or government agencies to
is a common and effective part
ensure that they are asking
of our health care system,” said
questions that are important
Gross, who is leading the planning of the NCSP at Yale. The
decision to include nursescholars in the NCSP builds
upon the interdisciplinary
framework of the RWJF program,

to stakeholders and that the
results of their studies will have
an impact. Scholars will build
upon collaborations that have
grown with the existing clinical scholars program, which
has included such partners as
the VA Connecticut Healthcare
System, Yale-New Haven
Hospital, Columbus House,
Integrated Refugee & Immigrant
Services, Project Access of New
Haven, and New Haven Family
Alliance, among others. “One
of the hallmark features of the
scholars program has been the
link between scholarship and
action,” said Gross. “We place
a great emphasis on teaching
scholars not just how to do
research but also how to instill
change, working either from
within the health care system or
from outside the system.”
While the NCSP is aimed
at early-career, post-training
physician- and nurse-scientists,
the trend toward interprofessional education, or IPE,
increasingly appears at all levels of medical education. The
Liaison Committee on Medical
Education, an accreditation
body, has established a new
standard that requires medical schools to include collaborative education as part of
their core curricula. At Yale,
when the School of Medicine
redesigned its curriculum,
Eve R. Colson, M.D., professor of pediatrics, joined with
colleagues from the School
of Nursing and the Physician
Associate Program to add an

Autumn 2015
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Alumnus Vivek Murthy,
M.D. ’03, M.B.A. ’03,
returns to Yale as the U.S.
Surgeon General.
Lessons from the
Ebola crisis at this year’s
Global Health Day.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.
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IPE component to the course
she leads, the Longitudinal
Clinical Experience. Th at program places medical students
in community-based clinical
settings from their fi rst days of
medical school. Now, fi rst-year
nursing and physician associate
students are also included,
said Colson.
Having the NCSP at Yale will
contribute to IPE’s goal of collaboration, Colson said, by providing students with role models
for how to work together across
professions. “How many hours
does a basketball team practice together before they play a
game?” said Colson. “Whereas
in medicine, all of us who take
care of patients, we don’t really
practice together. We just play
the game.”
Gross said the four-member
consortium is eager to get
started on the NCSP, which will
accept up to 25 scholars across
all sites for the program’s fi rst
cohort in 2016, with the hope
that new institutions will subsequently join the founding sites.
“It was really exciting to see
how the leadership at the four
university sites really banded
together,” Gross said, “and
realized that the whole would
be greater than the sum of our
parts if we continued to work
together. Th is really shows that
the benefits of working in teams
applies to large universities, just
as it applies to individual clinicians and researchers.”
—Jeanna Canapari

»

Health and the justice
system

As an intern on an emergency
department rotation at the
University of California, San
Francisco, in 2003, Emily Wang,
M.D., was shocked to learn
that many of her patients had
recently left prison, some within
the past few days. Equally
shocking, she realized, was
that for many of these patients,
prison offered them their fi rst
access to health care.
The U.S. Supreme Court
has ruled that health care for
inmates is required by the
Eighth Amendment to the U.S.
Constitution. Upon an inmate’s
release, however, the mandate
disappears and significant barriers to care arise. Most newly
released inmates have no primary
care providers and no insurance,
and do not know how to navigate

the health care system. For the 85
percent of inmates who received
regular care in prison for such
chronic conditions as diabetes
and hypertension, one of their
first stops upon release is the
emergency department.
“To me,” said Wang, an associate professor of medicine, “that
was an incredibly inefficient way
to run a health care system. It was
frustrating. It was inhumane.”
In 2005, during her last
year of residency, she began
the Transitions Clinic Network
(TCN) to help recently released
inmates adjust to life outside
prison by providing access to
health care. What began as
one clinic in San Francisco has

M AT T D A L E Y I L L U S T R AT I O N

grown into 15 clinics in seven
states and Puerto Rico, with
plans to expand. TCN has two
clinics in New Haven, at the Yale
Primary Care Center and the
Cornell Scott-Hill Health Center.
This is how it works: TCN
community health workers, all
of them former inmates, meet
former prisoners on their release.
They help patients get insurance,
see a primary care physician, and
connect with services to help
with housing and employment.
Kathleen F. Maurer, M.D.,
MPH ’85, director of Health and
Addiction Services and medical director of the Connecticut
Department of Correction, views
the peer advocate aspect of
TCN as crucial. “These patients
relate to their peers in a way
they couldn’t relate to a physician,” she said. In Connecticut,
inmate patients are released with
a four-week supply of medication and get help connecting to
Medicaid, often their only source
of insurance. Maurer said that
the Department of Correction
relies on TCN to help them stay
connected to health care.
The criminal justice system
has an enormous scope: 63 million Americans have criminal
records, and 13 million move in
and out of correctional facilities each year. It’s clear from
medical literature, Wang said,
that poor health can prevent
former inmates from getting a
job, and employment is one of
the most important factors in
helping them stay out of prison.
Data from TCN show that former

inmates who saw a primary
care physician within a month
of release had fewer emergency
department visits and hospitalizations than those who did
not. “It seems like a place where
the smallest sorts of adjustments
can make the biggest gains,”
Wang said.
With funding from the Yale
Center for Clinical Investigation
and the Patient-Centered
Outcomes Research Institute,
Wang and her colleagues are
developing a Web-based platform that will disseminate
to TCN clinics, patients, and
community stakeholders the
data she has collected through
nationwide studies of TCN
patients. TCN has also formed
a partnership with Yale Law
School to help TCN patients in
New Haven address legal needs
related to housing, employment,
and other social issues related
to the health of former inmates.
“There won’t be a singular solution,” Wang said, to addressing
the criminal justice system’s
impact on health equity, “but a
collective one.”
—Jeanna Canapari

»

Safer hospital transitions

Every year Yale-New Haven
Hospital (YNHH) admits more
than 50,000 patients. Once in
the hospital, patients may move,
for example, from the emergency
department to intensive care or
from medicine to Smilow Cancer

Hospital. Each of these transfers
carries a degree of risk. Health
care providers and hospital
administrators have long studied
the “handoff,” when a new doctor takes over patient care during
a shift change or a move from
one service to another and crucial information can fall through
the cracks. But now a team of
doctors and providers is taking a
broader look at those transitions
to anticipate problems and find
ways to mitigate them.
Over much of the past year,
Alana Rosenberg, M.P.H., has
spent many hours in the hospital
standing in hallways, at nurses’
stations and, in the emergency
department, watching residents,
attending physicians, nurses,
business associates, and patients.
With an anthropologist’s eye,
Rosenberg, a research associate in internal medicine, is part
of a team that observed those
moments when a patient enters
the hospital, moves from one
part of the hospital to another,
or leaves the hospital for home,
hospice, or a care facility. Then
the team interviewed the people
involved—doctors, nurses,
staff, and patients. Part of the
impetus for the study comes
from the Institute of Medicine’s
1999 report, To Err Is Human:
Building a Safer Health System.
The report, which estimated
that between 44,000 and 98,000
people die each year because of
preventable medical errors, convinced clinicians and investigators that new studies of patient
safety were needed.

Autumn 2015
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Welcome to the Class
of 2019! A new class
dons the white coat.
A clinic founded by
Yale med students expands its reach in the
wake of Nepal’s devastating earthquake.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.
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“Patients are moving through
the health system at a very fast
pace, and the technology that
we have is increasingly complex
and sophisticated,” said Sarwat
Chaudhry, M.D., FW ’05, associate professor of medicine. “The
diagnostic evaluations that
we’re doing and the data that
we as clinicians are juggling
are mind-boggling compared
to 20 or 30 years ago. You really
need multiple checks and systems in place to make sure that
things are happening the way
they’re supposed to.”
While past efforts have followed the traditional route of
devising an intervention, testing it, and analyzing the results,
the Center for Healthcare
Innovation, Redesign and
Learning (CHIRAL) is taking
a new approach. Funded by a
grant from the U.S. Department
of Health & Human Services’
Agency for Healthcare Research
and Quality (AHRQ), CHIRAL
starts with an in-depth problem analysis of patient safety
in three areas, and then works
with clinicians and experts from
such industries as aviation and
engineering to devise solutions.
“We have a lot to learn from
other industries that are ahead of
medicine, where you just count
on the individual remembering to do the right thing,” said
Chaudhry, principal investigator
for the part of the project that
involves transfers within YNHH.
The other projects, headed by
Marc Auerbach, M.D., assistant
professor of pediatrics, and Grace

As part of a months-long study,
Alana Rosenberg interviewed
health care workers and patients
to find out what works and what
doesn’t work during transition
points in hospital stays.

Y. Jenq, M.D., FW ’04, associate
professor of medicine (geriatrics),
will look at patients entering
the Yale-New Haven Children’s
Hospital emergency department, and patients moving out
of YNHH into skilled nursing
facilities. “Clinical deterioration
can happen during transport
because you’re not monitored
like you were on a floor,” said
Beth Hodshon, J.D., M.P.H., R.N.,
project director for CHIRAL.
CHIRAL, a joint venture
between the School of Medicine
and YNHH, was among the first
centers funded by the AHRQ initiative. “We’re one of the largest
health systems in the country,”
Chaudhry noted. “We have the
medical school and a world-class
hospital and health system, but
bringing together expertise from
both sides and both perspectives
was an important opportunity.”
Following a year of ethnographic observations for each
of the three projects, CHIRAL
looked at such specific issues
as communication, handoffs,
and data flow. Team members

observed and interviewed
everyone involved in transitions—health care providers,
ancillary staff, business associates, and patients—while the
data team studied information
collected in Epic, the electronic
medical record. In August, the
team met with national and
local experts to study interventions that might be effective. Unlike traditional studies
that end after an intervention
is tested and the results are
reported, the interventions
devised by CHIRAL will be
continuously designed, implemented, and tested in a process
that will end only when a solution is shown to be effective.
“Protocols can be put in place,
but it’s everyone’s reaction
[to how things are done] that
really matters in the end,” Rosenberg said.
—Jill Max

a collection of recent
scientific findings
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		 THE BUZZ
ABOUT HIV
Men with detectable HIV infections need less alcohol to feel
“buzzed” compared to uninfected
men, according to recent work
by researchers from Yale and the
Veterans Health Administration.
Survey responses from over 2,600
men in the Veterans Aging Cohort
Study, 607 with detectable HIV
infections and 871 with suppressed
HIV, showed that men with detectable infections need a quarter of a
drink less than their counterparts to
feel the effects of alcohol. “All else
equal, people who have HIV infection have a lower tolerance for alcohol than similar people without HIV
infection,” said Amy C. Justice, M.D.
’88, M.Sc., Ph.D., professor of medicine and public health and senior
author on the study. The study was
published in April in the journal
AIDS and Behavior.

		 GENE-EDITING
CYSTIC FIBROSIS

It might be time to toss those clunky
paper field guides. Researchers from
Yale and the University of Florida just
unveiled a new smartphone app called
Map of Life to track plant and animal
species around the world. The app is
based on a global scientific database
that launched in 2012 to catalog biodiversity. Users can not only see an
informative list and photographs of
all the species in their area, but also
contribute their personal observations.
“This vast information, personalized
for where we are, can change the way
we identify and learn about the things
we see when traveling, hiking in the
woods, or stepping in our own backyard,” said Walter Jetz, M.Sc., D.Phil.,
associate professor of ecology and
evolutionary biology, and the visionary
behind Map of Life. To download the
app, visit http://mol.org/mobile.

Researchers have engineered a novel
way to correct one of the genetic
mutations that cause cystic fibrosis, a
lethal disorder of the lungs and digestive system, as reported in the April
issue of Nature Communications. Using
gene-editing technology, the team
combined healthy DNA with synthetic
molecules called peptide nucleic acids
that trigger repair near the cystic
fibrosis mutation and then delivered
the molecules in mice via biodegradable nanoparticles. They also tested
the treatment on human cell cultures.
“The percentage of cells in humans and
in mice that we were able to edit the
CFTR mutation in using these nanoparticles containing triplex forming
peptide nucleic acids was higher than
has been previously reported with any
gene-editing technology,” said Marie E.
Egan, M.D., professor of pediatrics and
the study’s senior author. “This is step
one in a long process. The technology
could be used as a way to fix the basic
genetic defect in cystic fibrosis.”

		UNLIKELY
VIRAL ALLIES
Lassa virus, which can cause deadly
hemorrhagic fever similar to Ebola, and
was first described at Yale in 1969, kills
approximately 5,000 people a year,
according to the Centers for Disease
Control and Prevention—but now it’s
helping in the fight against brain cancer. VSV, a virus related to rabies, previously showed promise getting past
the blood-brain barrier and targeting
cancer cells, but it could also cause a
potentially lethal brain infection. Yale
and Harvard researchers used viruses
in which VSV proteins were replaced

with portions of the Lassa virus, creating a safe “chimeric” virus that successfully destroyed brain tumors in
mice without causing disease, according to a study published in the April
issue of Journal of Virology. “We are
very excited about these new chimeric
viruses that contain genes from multiple viruses. They work well in targeting
cancer in animals, and we hope that
they will also work effectively if tested
in humans,” said Tony van den Pol,
Ph.D. ’77, professor of neurosurgery
and the study’s senior author.
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Your entire brain is memory—
and your memory is who you are
M EMORY FA SCI NAT E S US. We’ve created a genre of literature we call

memoir. We take our memories and toy with them until they form a
coherent narrative, one that makes sense of our lives and allows us to live
with things we might like to forget. We’re embarrassed when we have
a “Rick Perry” moment and can’t retrieve from our brain something that
should be on the tip of our tongue. We recall vividly a night from 10 years
back but can’t remember what we discussed at last week’s staff meeting.
And we know that our memories are not set in stone, and that we can be
induced to “remember” events that never happened.
Neuroscience tells us that memories are patterns of synaptic connections
among the billions of neurons in our brain. Where our memories are stored
depends on what kind of memories they are. Is this phone number destined
to be a short-term memory, staying in our brain just long enough to dial?
Is this memory procedural, involving motor skills like tying a shoelace or
strumming a guitar? Is it traumatic or emotional, requiring the services
of the amygdala to process? Is it a semantic memory, the kind of fact that
keeps us up at night while we cram for a test? The brain has a spot for each
of them, but we still don’t know where all of our memories reside.
This issue of Yale Medicine is devoted to these notions of memory and
different ways to understand them. We asked doctors who write for their
perspectives on how and why we turn our memories into stories. Doctors tell
us why Alzheimer disease, which erodes our memories, is one of the most
feared disorders in the country.
As Oscar Wilde put it, “Memory is the diary we all carry about with us.”
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How circuits of neurons become
the narratives of our lives.
By Karen Zusi
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What is memory?

		“Close your eyes and

think of a lollipop,”

instructs Marvin Chun, Ph.D., professor
of psychology and neurobiology. “Now,
if I test you a week later by showing
you a picture of a lollipop and asking,
‘Did you ever see this?,’ you’re probably
going to say yes even though you just
imagined it.”

14
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Memory is a story. The entirety of our lives, real and
imagined, is grounded in memories of learning, thinking, and doing, making our memories inextricably
linked to our identities. Every time you recall something, a series of neurons lights up your brain, covering
it like a patterned spider web of energy. Remembering
the details of where you were, whom you were with,
and what an event looked or sounded like causes your
brain to activate and occasionally modify this pattern.
Like a children’s game of “Telephone,” details can get
altered or lost in translation; the brain doesn’t operate
like a perfect videotape. But its changeability ensures
that we can create and store memories in vast numbers of adaptive neural connections, constantly adding
threads to the tapestries of our persons.

in both healthy and diseased brains. Eyewitness testimony is notoriously fallible due to missing or imagined
details. Psychologists have also conducted experiments
in which a subject takes a sheet of paper from someone behind a desk, who then bends down to retrieve
something. A different person behind the desk stands
up—and the subject rarely notices. The experiment isn’t
meant to embarrass people, or to point out how little
they remember about the people they just met, but
rather as an example of how they prioritize where they
direct their attention. In these cases, were the clients
later asked to recall what the person behind the desk

w h er e m em o ri e s sta rt

There’s a lot that scientists still don’t know about how
we form and store memories, but the beginnings of one
are easy to trace. All memories start with perception.
Through thinking, touching, hearing, seeing, tasting, and smelling, we process our surroundings and
things that affect us. “Today I walked into the door and
bumped my elbow,” offers Jessica Cardin, Ph.D., assistant professor of neurobiology, as an example. “You have
to have a context for that memory. You have to see that
you’re in your office.” In the brain, the cortex receives
all of this information from various systems and funnels it into the hippocampus, which creates associations
throughout the neural network. But from there, everything depends on what type of memory is being formed.
Muscle memory—learning how to play the piano
or ride a bike—uses a different part of the brain than
remembering how you celebrated your birthday last
year. Spilling coffee on yourself during a meeting is
recalled differently from how to use a knife and fork,
which is different from remembering the dates you
studied for a history test the night before. Some memories are constantly reinforced by our environments and
therefore made stronger—it’s easier to forget where you
placed your keys last night than it is to forget the route
from your home to the office.
Mistakes, however, often occur in the perceptual
phase. “People are terrible observers most of the time,”
says Cardin, who studies the interplay between neurons
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What is memory?

looked like, odds are they would offer only general
details: gender, or perhaps race.
For items or events to which we do pay attention, we build chemical connections to consolidate a
memory. Compared to the number of neurons in the
average brain, a single person will have a seemingly
unlimited number of experiences. “You can’t assign
one memory per neuron,” says Cardin. Even with 100
billion neurons, there simply aren’t enough. Instead,
rather than selecting one cell to hold all memories of
a family member, we create a pattern involving only a
portion of the available neurons, combining them in
different numbers and sequences.

a d i sc r e te “t h i n g” i n t h e b r a i n

Researchers once envisioned memory as a discrete
“thing” in the brain, but now they search for these patterns of replay that indicate information being recalled.
Your brain can ignite the pattern for recall in multiple
ways, along any part. According to Cardin, smell is one
of the best ways to activate a memory. The nerves that
react to and process smells in the air connect directly
to the limbic system—which includes the hippocampus. We can also ignite patterns of recall by envisioning specific details or places. If someone asked you to
remember something about your childhood, you might
start with an image of your elementary school building
or your first pet and build from there.
When we reactivate such a neural recall pattern, it
becomes malleable. It’s unlikely that anyone would
believe they actually saw a lollipop since reading Chun’s
instructions, but that might change a week later if subjects were unaware of the test’s purpose. Memory is
like a wax seal, Chun says: First, you heat up the wax to
press an imprint into it, which then solidifies. But the
act of retrieval warms up the wax again. “That malleability—the fact that it becomes reprogrammable—that
physical fact is what allows memories to become stronger or weaker,” says Chun. “There’s no such thing as
reading out exactly what was encoded. It all involves
opening the files, making the wax warm again, because
we’re just dealing with proteins in the brain.”
False memories can be created by something as simple as a leading question. “You can do it experimentally
by having people witness an event,” says Cardin. A

subject might observe a brown-haired person bumping
into someone, with an experimenter afterwards asking the witness what time the blond person bumped
into the other. A week or two later, when asked to
describe the event, the witness is more likely to say
that a blond-haired person bumped into someone. The
immediate follow-up by the experimenter is crucial;
when recalling the event later, the witness’s brain activates the pattern of neurons and therefore heats up the
wax again, allowing the memory to be modified by the
suggestive question.
Change occurs to some types of memory more easily
than others. Memory of our personal timeline, referred
to as “episodic memory” or memory with a date and
time stamp, is most susceptible to alteration or decay.
The memory of what you gave a friend for a birthday
or who attended the party is less resilient than the
memory of what purpose a chair serves. Similarly, forgetting that the sky is usually blue or that a zebra is
striped would be unlikely without some type of brain
damage. These learned memories, ingrained factual
information outside our personal experiences, are
categorized as “semantic memory.” Psychologists still
debate whether the brain handles the information in
one system or two and how much reinforcement the
brain needs before a fact becomes part of semantic
memory, but no one argues that a distinction exists.

t r au m a a s a re se a rc h to o l

Traumatic brain damage and neural disease provide
critical information about what memory is and how it
works. Some of the brain’s memory systems are particularly robust. While episodic memory is often the first
to go, skill memory—the eponymous “muscle memory”
—is one of the most resilient. Even amnesiacs don’t
forget how to walk. Those who have difficulty forming new personal memories can still learn new motor
skills, including complex tasks like writing backwards
on a mirror. The brain stores skill memory in a different region from plain information.
When humans do forget things, the process may
occur in a few different ways. The act of trying to
remember is akin to searching for something on a
computer hard drive or in a messy room. If the computer files are organized, or the room has been recently
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cleaned, the search is easier—but with time and
entropy, finding things becomes difficult. “Memory
is the exact same thing,” says Chun. “Sometimes, it’s
hard to find because of all the other stuff.” Whether
memory patterns, if formed through proper attention,
can ever be truly “deleted” from our brains is still an
open question in psychology. However, they decay and
can be overwritten by more important information.
This notion of forgetting or lost memories has long
been a source of fascination for pop culture. Movies
across all genres deal with the topic: The Notebook
for Alzheimer disease; Memento or 50 First Dates for

anterograde amnesia, in which the main characters
cannot form new memories; The Bourne Identity
and Eternal Sunshine of the Spotless Mind for a more
science-fiction take on lost memories. “We don’t really
understand forgetting that well,” says Chun, but he
points out that an abnormal rate of memory loss is one
of the most debilitating situations in which patients
can find themselves: “It robs you of who you are and
how people relate to you.”
Clinically, forgetting as a process receives significant research attention. Even though memory patterns are spread throughout the brain, conditions
like Alzheimer disease hit memory the hardest of all
the brain functions. “What we can do to stave off and
understand that disease is probably our most pressing
challenge,” says Chun. “The more you can understand
memory and the more you can map it onto the brain,
and the more you can understand when it goes bad and
when you can preserve it—what all memory researchers do is helpful for that effort.”
But our brains have also created forgetting as an
adaptive function, and researchers are harnessing it
to treat other disorders. With chemicals that block
neurotransmitters, scientists are researching memory
alteration as a potential therapy for post-traumatic
stress disorder, drug addiction, delusions, and phobias.
By activating a memory and then using an agent that
weakens connections in the brain, researchers may be
able to remove the emotional attachment or craving
that accompanies the memory pattern and stop it from
being reinforced.
Memory as a higher brain function defines who we
are. We rely on our memories for experience, wisdom,
relationships, flexibility, and any ability to learn. Even
in Greek mythology, the Muses—goddesses of inspiration and knowledge in the arts and sciences—were
daughters of Mnemosyne, the goddess of memory. But
when our identities are predicated on a temporal continuity, what does it mean when it turns out we’re not
exact documentaries but some flavor of creative, narrative film? Our brains simply do the best they can—the
rest is up to us. /yale medicine
Karen Zusi was Yale Medicine’s writing intern in 2015.
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A T cell’s fate
Healthy humans are born with billions of infection-fighting
machines called T cells. We need so many because a
T cell exists for virtually every type of virus, bacterium, or
parasite. T cells respond to foreign intruders by replicating
like mad to generate an army of these defenders, including
killer T cells. As the infection clears, millions of those T cells
die off. Only 5 to 10 percent remain in the blood, poised to
attack like a boxer anticipating a familiar foe’s first punch.
These are memory T cells.
“Your immune system gets imprinted physically with
cells that are generated during the first infection,” said
Susan Kaech, Ph.D., associate professor of immunobiology
and a Howard Hughes Medical Institute early career scientist. This is why vaccines are so crucial, she said. The
immune system remembers the infectious agent so it can
ward off infections immediately, rather than letting nature
run its slower (and sometimes fatal) course.
But how do T cells become memory T cells? Scientists
had long assumed that the process was random and largely
governed by external forces. Research over the past decade,
however, suggests that certain T cells may be more intrinsically fit to become a long-lived memory T cell. During a
viral infection, some T cells express a receptor designed to
detect a cytokine called interleukin-7, and those cells live to
fight future infections. Most other T cells do not express that
receptor, and they don’t survive.
Yet research also suggests that environmental forces
might be at work. The more inflammation T cells are
exposed to, for example, the greater their chances of differentiating into killer T cells that can help clear the present

infection. This exposure, however, also makes them more
likely to die after an infection. In contrast, T cells only mildly
exposed to inflammation or to anti-inflammatory signals
are more likely to develop into memory T cells.
How such diversity of T cell fates arises remains a puzzle.
Are T cells born as either memory or terminal T cells?
“I think that would be kind of scary. It would be like predetermining the fate of a person while they were still in the
womb,” Kaech said, noting that infection is unpredictable,
never giving advance warning of which pathogen might
strike, when or where it comes from, and how much you’ll
be exposed to. In the face of such random events, the immune system must remain pliable. “You don’t know what
someone will become before they are born; and similarly,
you wouldn’t want your immune system deciding if a T cell
was going to live or die before it has even seen the pathogen it recognizes.”
—Kathleen Raven
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A memory’s journey
On their journey through the brain, our
memories pass through the hippocampus, a
temporary transit hub. Where they go next
depends on whether your brain is recording
the capitals of the 50 states, your reaction to
the latest Seth Rogen movie, or the shock of
witnessing a traffic accident.
For every memory, the brain creates a new

emotional charge of those experiences: the

are encoded and stored by the cerebellum,

circuit of neurons, or alters or strengthens

day I started med school … the time I spilled

putamen, caudate nucleus, and motor cortex.

an existing circuit. And each memory has
a context—it’s encoded in the brain based

coffee on my suit just before a job interview
… the first time I laid eyes on the love of my

Short-term memory, or working memory,
has been likened to a scratch pad where

on meaning and association. Long-term

life. These personal memories end up in

we jot down a phone number. Unless we

memories fall into two types, declara-

the medial temporal lobe and neocortex.

make an effort to retain that number, it will

tive and nondeclarative. Under declara-

Anything emotional or traumatic involves

disappear. The central executive part of the

tive memories—which are encoded by

the amygdala. Semantic memories are the

prefrontal cortex handles these types of

the hippocampus, entorhinal cortex, and

things outside of our personal experience

memories. Ever wonder why we break up

perirhinal cortex, but consolidated and

that we learn, say, from textbooks. What’s

phone numbers and credit card numbers?

stored in other parts of the brain—come

the capital of Estonia? When was the Battle

That’s “chunking,” breaking a long number

episodic memories. Episodic memories are

of Waterloo? Can you recite pi to 10 digits?

into chunks, which allows us to increase our

our personal experiences, including the

These types of memory reside in the lateral

short-term memory capacity.

and anterior temporal cortex and the prefrontal cortex.
Nondeclarative memory lets us remember how to ride a bicycle, strum a guitar, or
hammer a nail. These procedural memories
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There are things we just

“Mechanical memories,” which

Why do we write to-do lists?

There are things in our lives, like

remember, and the things we

we now call procedural memo-

Even our working memory has

slipping on the sidewalk and

work at remembering, like

ries, were first observed in

its limits. We use it to hold on

breaking an arm, that remain

studying for a test in microbiol-

1804. This is knowing how to

to something for as long as we

as episodic memories—the

ogy or American history. What

do things. These are the skills

need it and no longer—usually

stories of our lives. Somehow

year did Lincoln deliver the

we acquire and never forget,

just a few seconds. What’s the

we organize these memories

Gettysburg address? What’s the

like riding a bicycle. If you play

number of that takeout Chinese

into coherent narratives with

place? What’s that email ad-

a beginning, middle, and end.

difference between DNA and

an instrument it seems like

RNA? These learned facts and

the muscles in your fingers

dress? In the 1950s, it was pos-

Along with the broken arm,

figures outside of our personal

remember, too, and know ex-

ited that our capacity to hold

we’ll remember where we were

experience become part of

actly where to strike that key or

on to information is limited to a

coming from, where we were

our semantic memory, but not

form that chord. Without even

handful of “chunks.” That’s why

going, whether we were dis-

everything in our semantic

thinking, we know, in a given

we break up long series of dig-

tracted by our cell phone, the

memory comes from text-

song, which note comes next.

its like our phone numbers or

ice on the sidewalk, the mo-

books. These memories can be

Procedural memory allows the

social security numbers. And,

ment of slipping, the realization

the facts common to our cul-

muscles in a quarterback’s or

as we age, working memory

that we were going to fall and

ture, like the name of our state

pitcher’s arm to throw the ball

is among the functions most

that it was going to hurt. But

capital or the current president,

with accuracy, and without

likely to decline.

and include other facts we

even thinking about it. Like-

pleasant—a Labor Day barbe-

acquire over a lifetime. Trying

wise, hammering a nail is one

cue at the beach with friends,

to cram all these things into our

of those skills that stays with

the conversation, the sound of

brain the night before a test is

you. Your muscles just know.

the surf, and the food. Through

episodic memories can also be

probably the worst thing we

these memories we travel back

can do. Research has shown

in time, from last weekend to

that we need to sleep in order

30 years ago.

O T T O S T E I N I N G E R I L L U S T R AT I O N S

to consolidate our memories.
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What’s in a doctor’s brain,
and what’s online
In the typical adult human, there are 206 bones, at least
700 named muscles, 78 organs, 12 pairs of cranial nerves
and 32 pairs of spinal nerves, and a formidable array of
named veins and arteries, all of which, during medical
training, a budding doctor will be asked to commit to
memory. That, of course, is only the beginning. There are
an untold number of procedures to memorize, as well as
a host of diseases—currently more than 30,000—to cram
into the cerebral cortex, and when the training process is
complete, assuming it is ever really done, physicians are
expected throughout their careers to dig into their brains’
hard drives and retrieve relevant information quickly, effortlessly, and flawlessly.
But in the modern technological era, when tablets
and smartphones are as much a part of a doctor’s regalia
as a white coat and a stethoscope—Yale students receive
iPads when they enter medical school—does it still make
sense to engage in all that memory work? Neurobiologist
Michael Schwartz, Ph.D., associate dean for curriculum,
said that’s a question worth exploring. With the explosion
of knowledge and the ease with which it can be accessed
by technology, he said, we need to be more thoughtful
about which facts need to be in the memory for immediate application. “Memorization takes up far too much
cognitive bandwidth when we should be focusing more
on the application of knowledge. Technology now gives
us the opportunity to access all that information instan-
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taneously, and this is changing the way we train doctors
and practice medicine.”
Internist Auguste H. Fortin VI, M.D., M.P.H., believes
that it’s mostly a change for the better. “Most of medical
education has revolved around filling up the empty vessel
with facts, but with scientific knowledge growing explosively, no one can possibly keep it all in mind,” said Fortin,
who teaches communication skills and always has his
iPhone handy in the exam room.
While there had been fears that computers of any
variety would be seen by patients as intrusive, those worries haven’t played out. “I’ll tell patients when I’m looking
something up that I’m almost positive about the condition,
but I just want to double-check and make sure my recollection is correct,” Fortin explained. “And I show them
what I’m doing so they know I’m not texting or checking
my shopping list. The iDevice has become a partner, a way
to ensure quality control and improve patient care.”
The fact that Fortin is less reliant on memory is a big
plus since he freely admits that his memory is less than
photographic. “I remember sometimes having to invent
a pretense to leave an examination room so I could go
back into the office to look something up in a book,” he
explained. “There was a bit of shame in this—I didn’t want
a patient to know that I didn’t have it all in my head.”
That shame is gone, but while Fortin may not have
the entirety of Harrison’s Principles of Internal Medicine
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at his cognitive fingertips, he has all of his specialty’s
typical procedures, to say nothing of an impressive array
of facts, at his disposal. This doesn’t include the proper
dose of every medication imaginable—these are readily
available online—but Fortin and his fellow internists know
by heart the proper flow of a patient encounter and the
skills needed to draw out a patient to effect a differential
diagnosis. “You memorize the more common situations,
like if you see someone with chest pains who has these
particular qualities, you might be looking at diagnosis A, B,
C, or D,” he said. “You vaguely recall that there could also
be E or F, but you’d have to look up the specifics.”
The emphasis on methodology rather than memorization is where medical training is heading. “We’re actively
trying to determine the base level of knowledge a physician absolutely requires to do the job, especially in an
emergency when you simply don’t have time to look
things up,” said Schwartz. “Figuring this out is one of the
primary challenges of modern medical education.”
But if the jury is still out on precisely what a doctor
needs to memorize, the proper habits of mind are clear in
the iAge—or any age. “One of our central tasks as teachers
is to instill in students the value of looking things up and,
of course, teaching them where to obtain the highest and
most reputable quality information out there. This is where
medical research librarians are worth their weight in gold,”
said Fortin. “You have to be confident in what you know,

as well as confident that you can find out what you don’t
know or can’t quite remember. But above all else, you
can’t forget that the patient—not the iPhone, tablet, or any
other iTool—is your focus. These devices are just another
way to make sure that you have things right.”
— Bruce Fellman
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The things we remember become
tales with morals and meanings.
By Jenny Blair

Sophie Casson Illustrations
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Our memories, our stories

As chief resident
on the arduous Osler
service at Johns
Hopkins in the 1960s,
Thomas P. Duffy, M.D., was asked to verify
the suicide of a young nursing student.
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Alone, he entered her room and found the student
upright in bed, dressed in lace, stained with vomit,
dead from an overdose of sedatives. A supervisor soon
joined him and asked Duffy to fill out death forms and
search the room for anything embarrassing. He found
a risqué snapshot of a happy young man wearing only
combat boots.
Minutes later, Duffy hurried to grand rounds.
Determined to maintain equanimity, he chose not to
discuss or even think further about the young woman’s death or his role in sanitizing it.
Years later, as a professor of medicine at Yale, Duffy
sat down to write an article for the journal The Pharos
about his Hopkins years. As he thought back, the
memory of this incident returned full force. For the
first time, he mentally revisited the young woman’s
deathbed, and he included her story in the article. His
failure to acknowledge the young woman’s death had
been callous, he wrote, while his need to put it out of
his mind illustrated a system that was unaware of the
emotional disruption that encounters with tragedy
could trigger in young doctors. The program’s pyramid
system winnowed half of each residency class annually
while demanding what Duffy wrote was an “almost
superhuman effort” and a “conspiracy of silence”
about traumatic experiences. For the house staff, he
wrote, this training amounted to “self-torture.”
Duffy believes it is important to share such experiences. “If one does not address moments like that,
at some point in the future one pays the toll,” he said.
“It comes back to haunt you.”
Denial and machismo hardly make for healthy souls.
Yet studies of interventions for post-traumatic stress
disorder (PTSD) show that recounting a traumatic
incident right away can sometimes mean worse stress
symptoms later, too. Stories that bring healing and
insight can take time to assemble from the raw material of the memory. Decades, even.
Narrative underlies most, if not all, of our attempts to
make sense of the world. Yet the links between memory
and stories are many and complex. Memory is less like
a set of index cards and more like a set of systems that
direct decisions, many unconscious, about how to
reconstruct and interpret events in the past. From such
decisions, stories arise. How these processes take place,

how they heal or harm, how faithfully they affect reality, are by no means straightforward questions.
To create compelling stories aimed at other readers, fiction writers draw upon their own experiences.
But too much reliance on memory can paradoxically
weaken prose, according to novelist Bret Anthony
Johnston, who urges his writing students to buck the
advice “Write what you know.” By all means, he writes
in a 2011 essay for The Atlantic, set stories in a familiar
setting and festoon them with details from memories.
But then route the plot away from memory. Let characters do things you’ve never done. Fiction’s narrative
and emotional integrity can and should trump the literal truth of what happened.
“Stories aren’t about actions. Stories are, unto themselves, actions,” Johnston writes.
Medical professionals who want to write accounts
of their patients are faced with a practical and ethical
concern: how to conceal patients’ identities and protect
their privacy. Anna B. Reisman, M.D., associate professor of medicine and co-director of a writing workshop
for residents, recommends that residents (and any
health care professional writing about patients) either
remove enough detail to hide patients’ identities or
ask their permission, which is also fraught with ethical issues. Ideally, one does both; another option is to
go beyond simple de-identification. Write a story, she
advised in The Atlantic in February, free from dependence on the facts of what happened. To Reisman,
fictionalizing a medical history not only is the more
clearly ethical option, but it can also yield truths independent of literal accuracy. “Sometimes, the truth can
emerge more clearly—and more kindly—through the
prism of fiction,” she writes.
The mind seems to think so, too, as memory routinely obliges the present by rewriting the past.
Eyewitness testimony is so malleable, its underlying
memories so subject to suggestion and prone to distortion, that it can wrongly convict a defendant. The 1980s
recovered-memory movement sent many innocents
to prison after their accusers came to believe that they
had been abused as children, often encouraged by
well-meaning therapists to tell stories of rape or Satan
worship. Researchers now understand that false memories can be implanted by storytelling.
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Anna Reisman // Read more on page 44

“You read a great novel and you really empathize
		 with the characters, you get into their heads,
you see things from their perspective.
What better training to be a good doctor than to be
		 able to imagine what a patient is going through!

’’

In everyday life, too, simply recalling and retelling
memories can alter them. The act of retrieving
and reconsolidating a memory seems to render it
susceptible to change, as if we could reread only
while highlighting and crossing out. This effect is so
strong that researchers are looking to tweak it for
better PTSD treatments.
“In order to incorporate [memories] into the story,
what was vague has to become concretized. So no
question, we polish them,” Duffy said. “[Knowing]
how it all played out, now the memories are refracted
through a different prism.”
Stories can heal, a truth well-known to Annita P.
Sawyer, Ph.D. ’81, assistant clinical professor of psychiatry and a practicing psychotherapist. In 1960, as
an adolescent traumatized by family abuse, Sawyer
was misdiagnosed with schizophrenia, hospitalized,
and subjected to shock treatments that erased much
of her memory. She built a successful life, keeping
the hospitalization a secret. But in 2001, she decided
to read her own medical records from that longago time.
Disturbing memories rushed back, shaking her
deeply. Clinical experience told her that she must have
had PTSD back then, not schizophrenia. Compelled
to rethink her own identity, she realized she had a
story to tell.
During the decade that followed, as Sawyer read,
remembered, and wrote, an ingrained feeling of disconnection from daily life gradually disappeared.
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So did her lifelong shyness. Her life story retold
lost its frightening energy, and she felt whole.
She published Smoking Cigarettes, Eating Glass:
A Psychologist’s Memoir last spring.
Whether in therapy or in memoir, Sawyer says,
constructing a true story allows another person to
hold your experience, helping transform “inchoate, churning” memories into something orderly and
coherent. (Her patients’ lives are so much like novels,
she says, that she has no trouble remembering all the
characters from their stories.)
Even if this story doesn’t perfectly correspond to
reality, even if it’s filled with the kind of ugliness her
book’s title suggests, a story based on truth can restore
a fragmented sense of self.
“People don’t have to have prettiness,” Sawyer said.
“People don’t need a story to be pretty; they need it to
make sense.” /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.
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Can ginkgo tea preserve our memories?
Fish oil, ginkgo tea, dark chocolate, and periwinkle extract
have all been touted as brain enhancers, along with countless infomercial pills. But do any of them preserve memory as
we age? Says one Yale neurologist—well, forget about it.
“Dietary supplements have pretty much failed,” says
Jaime Grutzendler, M.D., associate professor of neurology
and neurobiology and director of the Center for Experimental
Neuroimaging. “Vitamin B12, vitamin E, vitamin C—all the
studies that have been done so far have not shown any longterm benefits.”
For Grutzendler, Alzheimer disease and other brain conditions are the ultimate challenge. His lab studies different
pathologies in the brain using real-time cellular imaging; like
early astronomers gathering information by watching the
night sky, he enters research with no agenda. He just wants
to find out how things work. “We don’t have a preconceived
notion of what the system should do or how it should deteriorate,” he says. With these methods, Grutzendler’s work has
shed light on theories about how we fall into cognitive decline.
The causes of cognitive decline are nearly as varied as the
supplements sold to prevent it. In his office, where Pollocklike images of fluorescent brain cells decorate the walls,
Grutzendler points to a series of images on his computer
screen. They depict structures in the brain associated with
dementia, primarily the plaques famously found in Alzheimer
patients and the lesser-known but no less common neurofibrillary tangles. These tangles are built-up proteins inside
neurons, as opposed to plaques, which form outside the cells
and can cover large portions of the brain. They both interfere
with cellular signaling.

Aging itself is associated with plaques and tangles, which
lead to some degree of cognitive slowing and potential
memory loss. But they don’t always appear in the same places
or at the same times. “Aging is complicated,” says Grutzendler.
“Aging is not one disease. It’s the disease of almost everything,
like an old car—basically, everything starts to fall apart in some
way.” Neurologists look at different types of damage in the
brain that may lead to the same symptoms, just as a dead battery or a faulty ignition switch both mean a car won’t start.
So, are all humans doomed to some form of cognitive decline if we live long enough? Grutzendler speculates yes—but
not all hope is lost. Supplements haven’t worked conclusively
in preventing or slowing dementia, but vascular health—
making sure your circulatory system gets blood to body parts
that need it—is important at any stage of life. And factors
affecting vascular health aren’t so difficult to pin down.
Uncontrolled diabetes, obesity, hypertension, and
smoking are all associated with damage to small blood vessels in the brain. When these vessels are affected, less blood
makes it to the neurons, weakening their connections. Scientists haven’t yet demonstrated a bulletproof connection
to cognitive decline, but Grutzendler concludes that these
are serious risk factors.
Sleep is another factor believed to affect cognitive health,
though those links have not been fully demonstrated. The
best science, however, still tells us that sleep, exercise, good
nutrition, and control of such risk factors as smoking and
high blood pressure are some of the keys to a healthy lifestyle—and a healthy brain.
—Karen Zusi

Autumn 2015

31

Misplaced keys and forgotten appointments
are among the episodic memories that are
lost to Alzheimer disease. Yale clinicians
and scientists are looking for new ways to
predict the disease and find a cure.
By Ashley P. Taylor Matthew Daley Illustrations
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It was at his maternal
grandparents’ 50th
wedding anniversary
that Chris H. van Dyck, M.D., first noticed
something different about his grandfather.
The retired Presbyterian minister, then 83,
was at the head of the table making a speech
to old friends. “He looked like Granddad there,
doing his thing. And he was reasonably
coherent,” van Dyck, then about 20 years old,
recalls. Until he’d finished the speech. “I went
over to him and said, ‘Hello, Granddad,’
and he looked at me and said, ‘Who are you?’ ”
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That was the summer of 1975, and van Dyck’s grandfather was in the beginning stages of Alzheimer disease,
an illness that would later claim both of his maternal
grandparents, and which van Dyck, a geriatric psychiatrist, would study as the director of Yale’s Alzheimer’s
Disease Research Unit.
Alzheimer disease is characterized by a gradual
loss of what, arguably, makes people who they are:
their memories. It starts with innocent forgetfulness.
“Usually the first thing to go is episodic memory,” says
Arash Salardini, M.D., co-director of Yale’s Memory
Disorders Clinic, referring to memories with specific
contexts in space and time. “Based on that, you can see
what sort of memories usually go first. People misplace
things. They forget appointments.” People first lose
the ability to form new memories, while long-term
memories—the sort van Dyck’s grandfather was probably recounting at the anniversary—are more resilient.
As the disease progresses, people start to lose executive
functions: the ability to make and carry out plans. They
lose interest in hobbies; they can no longer use the
phone, drive a car, or balance a checkbook. Eventually,
they can no longer attend to their own basic needs
and become dependent on others. In the United States,
Alzheimer disease ranks high on the list of diseases
people most fear.
After van Dyck’s grandfather became ill, van Dyck
says, his mother bought her parents a house near her
home in northern Vermont so that she could take care
of them. As the grandfather’s dementia progressed,
van Dyck’s mother ended up hiring nearly 24-hour
live-in care. Almost immediately after his grandfather
died, van Dyck says, his grandmother began to show
signs of memory loss, too; she died of Alzheimer
disease a few years later. Then his mother’s second
husband, van Dyck’s stepfather, got the disease, and
his mother cared for him until his death. “She was
immersed in Alzheimer disease,” van Dyck says. His
mother, now 89, shows no signs of dementia.
Though he believes his choice to focus on Alzheimer
disease was in part intellectual, van Dyck feels that
his family history also nudged him in that direction.
“Seeing my mother do heroic work caring for these
people was impressive, and showed what that was like
for families and the need for treatments.”

a di se a se t h at def i e s di ag n osi s

In the past, Alzheimer disease could be definitively diagnosed only upon autopsy. Doctors observed two kinds of
brain pathologies: large plaques of a protein called beta
amyloid crowding the spaces outside neurons, and inside
them, what are called neurofibrillary tangles of another
protein, tau. An accurate clinical diagnosis relied on the
results of memory and neurological tests and ruling out
other potential causes of dementia.
Van Dyck began utilizing neuroimaging to study
the aging brain. He and Yale colleagues (including
Richard E. Carson, Ph.D., director of the Yale PET
Center) were among the first to adapt Single-Photon
Emission Computed Tomography (SPECT) and positron
emission tomography (PET) to visualize molecules
in the brain. In conjunction with the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) of the National
Institutes of Health, van Dyck and the Alzheimer’s
Disease Research Unit have helped to evaluate PET
imaging methods to visualize pathological changes in
the brain linked to Alzheimer disease.
In the past 10 years, the ADNI consortium, along
with other research teams, has demonstrated that PET
imaging could be used to visualize beta amyloid in
the brains of patients with Alzheimer disease and that
markers of beta amyloid could even be seen in people
at high risk for the disease before the onset of symptoms. Based on this work, amyloid PET scans are now
approved for use in the diagnosis of Alzheimer disease.
For Salardini, PET scanning is an important diagnostic tool, particularly when trying to distinguish
Alzheimer disease from other types of dementia. These
brain scans have also brought new understanding
of the disease itself. Alzheimer disease’s hallmark
amyloid plaques, researchers have found, accumulate
decades before symptoms arise. Using PET scans, doctors are getting better at diagnosing Alzheimer disease
and at determining who is at risk for developing it,
paving the way toward early interventions.
“You don’t want to treat the disease once the manifestations occur and you already have memory loss,”
says David Hafler, M.D., M.Sc., chair of neurology
and neurologist-in-chief at Yale-New Haven Hospital.
Instead, you want to use multiple tests to determine
who’s at risk and “get patients on treatment before they
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develop the disease. That’s my vision for what we want
to do at Yale.”
The glitch, however, is that there is no treatment
for Alzheimer disease. Yale researchers are trying to
change that. One clinical trial is testing a drug that
interferes with a chain of molecular events—triggered
by beta amyloid—that causes the brain’s neuronal connections to break down. Another is testing whether
keeping beta amyloid from building up could prevent
Alzheimer disease.

Yale designated
research center by NIH
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h a llm a rk s o f a l zh ei m er di se a se

On a molecular level, Alzheimer disease is characterized
by the build-up of beta amyloid. Although neuroscientists still aren’t sure what it does, the beta amyloid peptide is part of the healthy brain, where it “gets made and
rapidly cleared,” explains Stephen M. Strittmatter, M.D.,
Ph.D., Vincent Coates Professor of Neurology, professor of
neurobiology, and director of the Yale Memory Disorders
Clinic. In patients with Alzheimer disease, however, beta
amyloid takes abnormal forms. Fibers clump together
outside neurons to form the disease’s iconic plaques.
But it’s a third type of beta amyloid, in which several
copies of the protein come together to form what are
called oligomers, that researchers suspect is a culprit in
Alzheimer disease. Unlike plaques, which are stuck in
place, the oligomers can float around in the brain, interacting with—and possibly destroying—neurons.
According to research from the Strittmatter lab,
these beta amyloid oligomers damage synapses—the
connections between neurons—creating gaps in the
brain’s communication system. Beta amyloid doesn’t
damage neurons directly—it starts a domino chain of
molecular events that shrivels synapses. In mice with
Alzheimer disease-like symptoms, the Strittmatter lab
found that using a drug to block one of the proteins in
this chain, called Fyn kinase, halted the damage and
allowed both synapses and memory to bounce back. To
see whether these results carry over to humans, van
Dyck is testing the drug (saracatinib) in a nationwide
clinical trial for people with mild symptoms.
Another clinical trial is testing whether an antibody
that binds to beta amyloid and removes it from the
body could prevent Alzheimer disease from developing
in the first place. When tested on Alzheimer disease

In a vote of confidence, the federal government has designated Yale as an Alzheimer’s Disease Research Center
(ADRC)—the medical school will receive funding from the
National Institutes of Health to compile and analyze data on
Alzheimer disease patients. The designation comes with a
five-year grant of more than $1.5 million per year that will
support many facets of Alzheimer disease research, including basic research, collection of clinical data, community
outreach, and education. The Alzheimer’s Disease Research
Unit, the Yale Memory Disorders Clinic, and the Dorothy Adler
Geriatric Assessment Center already provide excellent care to
Alzheimer disease patients. The grant will allow these groups
to synthesize their information and resources, thereby
fostering greater knowledge and advancing potential treatments, says Stephen M. Strittmatter, M.D., Ph.D. (in photo, at
left), the Vincent Coates Professor of Neurology, professor
of neurobiology, and director of the Yale Memory Disorders
Clinic, and principal investigator of the ADRC grant from the
NIH. He and Chris van Dyck, M.D. (in photo, at right), director
of the Alzheimer’s Disease Research Unit, co-direct the Yale
ADRC; Arash Salardini, M.D. (in photo, center), co-director of
the Memory Disorders Clinic, is its assistant clinical director.
“The ADRC is composed primarily of people at Yale who were
previously carrying out separate tasks. Through the new
center they now work as a team in the sense of meeting together, sharing ideas and reagents, and coordinating studies
across the translational research scale,” Strittmatter says.
As the search for a treatment continues, the number
of Alzheimer disease cases—an estimated 5.3 million
Americans in 2015, according to the Alzheimer’s Association—
continues to grow as the population ages.
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Arash Salardini //

“Almost everybody who has amyloid
deposition beyond a certain amount will get Alzheimer
		 disease, and almost nobody without amyloid
deposition has Alzheimer disease.

’’

patients, the overall finding was that the antibody
(solanezumab) did not work. In a subset of patients
with mild dementia, however, the drug slowed disease
progression by about a third, van Dyck says.
This finding prompted researchers to ask, as van
Dyck puts it, “What if you go milder than mild, all
the way to preclinical, presymptomatic? Maybe it’s a
question of intervening before too much brain damage is done.” The study is testing that hypothesis in
patients 65 or older who are cognitively normal but
who have abnormally high levels of beta amyloid, as
measured by PET scans. In the Anti-Amyloid Treatment
in Asymptomatic Alzheimer’s Disease (A4) Study,
which is still enrolling participants, half the patients
receive monthly intravenous infusions of the drug and
half receive a placebo. The study is “blind”—neither
researchers nor participants know who receives the
drug. At the end of the three-year study, a second PET
scan for beta amyloid will show whether the drug prevented the protein from accumulating, and “unblinding”
the results will reveal whether the treatment prevented
memory loss.
Whether or not removing beta amyloid from the
brain proves effective in preventing Alzheimer disease,
it is emerging as a key predictor of risk for the disease
and crucially, one that shows up long in advance of disease symptoms. “Almost everybody who has amyloid
deposition beyond a certain amount will get Alzheimer
disease, and almost nobody without amyloid deposition
has Alzheimer disease,” says Salardini, adding that such

38 yalemedicine.yale.edu

a build-up can begin 20 years before symptoms emerge.
One day, van Dyck predicts, screening for Alzheimer
disease using amyloid PET scans may be as routine as
getting a colonoscopy. “That is the kind of paradigm
we’re talking about,” he says. “We don’t even want to
wait until people have lost a bunch of gray matter; we’d
like to be able to intervene at an earlier stage.” But an
earlier, more accurate diagnosis will be most valuable
only when there’s a treatment. Without a treatment,
there’s no way to act on an earlier diagnosis.
“If we had an intervention that could save people,
[PET scanning] would just so obviously pay for itself,”
van Dyck says, noting that insurance doesn’t usually cover the scans. “The cost of a PET scan would be
trivial when you compare it to, besides the individual
costs, just the sheer economic costs to society.”
Strittmatter is optimistic that research will lead
to possible treatments, and he believes that the partnership between the new Alzheimer’s Disease Research
Unit and the NIH will advance that research.
“I think that research that is going on is opening
new doors. We have to find out which one will make
a difference for people.” /yale medicine
Ashley P. Taylor is a freelance writer in Brooklyn, N.Y.

N L S H O P I L L U S T R AT I O N

Stem cells also remember
The New England Patriots would never call a timeout midgame to proclaim their status as the weaker team. Animal
stem cells, however, confess their lesser rank to others all
the time. In a display of altruism, they send signals to neighboring cells about their levels of stress, oxygen, or nutrition.
Whatever their status, they serve a common goal—the fitter
the cell, the more competitive it is in the race to produce
healthy progeny.
Ruslan M. Medzhitov, Ph.D., the David W. Wallace Professor of Immunobiology, and his lab members are studying
how stem cells become winners or losers in this game of
reproduction. Stem cells, they have found, appear keen to
communicate a very technical aspect of their performance:
their past. A stem cell’s DNA bunched inside chromosomes
may look as good as new, but this doesn’t stop the cell from
remembering and divulging its history. If surrounded by
healthy cells, the cell with a previously repaired genome
will graciously back out of the race.
When Medzhitov injected mice with stem cells that
had been exposed to low-level radiation, histone proteins
rushed in to “bookmark” damaged regions of DNA. DNA repair genes mended the broken letters and several days later
turned themselves off. The histone proteins disappeared
and the stem cell’s genome appeared perfectly normal. But
a patch job is just that—a patch job. It doesn’t guarantee
against errors that might occur during the repair. This is why
previously damaged stem cells declare themselves in the
first place: they want to pass on only healthy cells to their
offspring. (Cancer cells, which don’t play fair, never blow
their cover by disclosing past damage.)

Medzhitov and his team believe that these memories of
damage and repair are stored in the form of slight mutations
in the telomeres, regions of repetitive DNA at the ends of
chromosomes. “It’s important to understand the selection
processes that go on in stem cells,” Medzhitov said. A better
understanding of how everything works could affect bone
marrow transplant patients, he said. This fragile patient
population needs lots of healthy stem cells so that their
blood-making, or hematopoietic, system has a long life
and is not rife with mutations that could later lead to such
health problems as cancer.
—Kathleen Raven

Autumn 2015 39

capsule
understanding of these differences through history.
“People think of freak shows
when they think about
extreme bodily abnormalities,” said Thompson, “but

		 The history of
human monstrosity
An exhibit at the Harvey Cushing/John
		 Hay Whitney Medical Library explores the
“marvel and wonder” of human abnormalities.
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TOP LEFT An anonymous

British printmaker of
the 19th century made
this lithograph of two
conjoined twins, Chang
and Eng Bunker, who
lived from 1811 to 1874
and were known as “The
Siamese Twins.” At the
time the lithograph was
produced, they were 18.

TOP RIGHT A 19th-

century poster touted
both the “curious
history” of both Julia
Pastrana, who suffered
from two undiagnosed
conditions that gave her
extreme hair growth
and thick gums, and
the “double-bodied
boy,” a boy with a parasitic twin, a rare type
of conjoined twin.

BOTTOM LEFT A London
handbill from 1825
advertised a showing of
Claude Ambroise Seurat,
"The Living Skeleton."
Seurat was born in
Champagne, France,
and as he grew, his soft
tissue, including flesh,
turned to bone.
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			 Tinker, sailor,
Golgi, sly
JA M E S D. JA M I E S O N, M .D., P H .D. , has spent a career dividing his time

among so many responsibilities—running a lab, directing a program,
mentoring students, among others—that it’s difficult to know how he found
time for lunches with students in Marigolds or harbor tours on his sailboat.
But Jamieson was always available to students in Yale’s M.D./Ph.D. program,
which he directed for 32 years. “The thing I learned from Jim was the care
and concern and gentleness with which he treated students,” said Michael
Caplan, Ph.D. ’87, M.D. ’87, chair and the C. N. H. Long Professor of Cellular
and Molecular Physiology, and professor of cell biology. Being a mentor,
Caplan learned from Jamieson, is a large part of being a scientist.
When Jamieson, professor of cell
biology, arrived at Yale in 1973,
his task was to launch a cell biology department. (He would later
spend eight years as its chair.) The
following year he became director of Yale’s Medical Scientist
Training Program, funded by a
grant from the National Institutes
of Health and known as the M.D./
Ph.D. program. The physicianturned-cell-biologist continued research he’d begun at The
Rockefeller University under the
guidance of Nobel laureate George
Palade, M.D. He studied the
mechanisms of secretion of proteins by the pancreatic acinar cell
and other cell types. He closed his
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lab in 2001 to devote
his attention to the M.D./Ph.D.
program, known more colloquially as “mud/fud.”
During his tenure some
300 students graduated from the
program; and with the recent
expansion of the program from
12 to 20 students per year, M.D./
Ph.D. students make up 20 percent of each medical school class.
“This makes Yale’s program one
of the largest nationally, reflecting Yale's preeminence in the
basic and clinical sciences,”
Jamieson said. In addition, he
said, electives that he started,
such as one in translational
medicine in pediatrics, “energize and feed positively into the
med school curriculum.”
Susan J. Baserga, M.D. ’88,
Ph.D. ’88, noted that Jamieson
can think critically about

research design with the same
ease with which he runs admission committee meetings. Sam
B. Sondalle, a fourth-year M.D./
Ph.D. student in her lab, came to
Yale in part because of Jamieson,
said Baserga, professor of molecular biophysics and biochemistry,
of genetics, and of therapeutic
radiology. When he met Jamieson
in December 2010, Sondalle said
he was struck by Jamieson’s
friendliness and his generosity in
offering advice. When Jamieson
learned about Sondalle’s interest in a rare genetic disease, he
introduced him to Baserga as a
potential research advisor. Given
Baserga’s extensive experience in
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After more than 30 years,
James Jamieson has
retired as director of the
M.D./Ph.D. program.
Students and mentees
remember his friendliness and generosity.

Autumn 2015 43

faces

ON LIN E E XC LU S IVES

Global warming
affects New Haven’s
poor and elderly.
A medical school curriculum should integrate
science and care, allow
for individual exploration, and develop lifelong
learners, said a speaker
at Medical Education Day.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.
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genetics, the match was a perfect
fit, Sondalle said.
Caplan described Jamieson
as down-to-earth and outgoing. “He had an extremely
paternal—in the best sense of
the word—connection to the
program and students,” Caplan
said, adding that Jamieson had
a “nitty-gritty, nuts-and-bolts
understanding of how to do
experiments.” Jamieson’s lasting
imprint on the program, Caplan
said, is his devotion to students.
Barbara Kazmierczak, M.D.,
Ph.D., associate professor of
medicine, infectious diseases,
and microbial pathogenesis, who
became the program’s director
last year, said she witnessed that
devotion at a Christmas party at
Jamieson’s house. Jamieson and
his wife, Cynthia, stayed up late
trading movie recommendations
with a handful of students. “It
was one of the moments when I
realized they were embedded in
the Yale community and really
loved New Haven, and thought
of students as family,” she
said. “He has the curiosity that
the best scientists have. And it
extends to curiosity about people,
motivations, and relationships.”
Regarding his accomplishments,
Kazmierczak highlighted a crucial decision that Jamieson made.
Rather than wait until after they
finish their Ph.D. training to
begin the required 12 months
of clinical clerkships, Jamieson
decreed that M.D./Ph.D. students
complete half their clerkships
before beginning their graduate
study. “With very few exceptions,

students value this protected
period of time when they see
how the book learning translates into taking care of patients,”
Kazmierczak said. “For some
of them, the clerkship period
informs the thesis they will do.”
Jamieson said he enjoys helping the M.D./Ph.D. students
blow off steam by offering rides
in his sailboat or helping out
with student video parodies for
the annual Second-Year Show—
for example a spoof on the
Disney movie Frozen—produced
by the Class of 2017. Jamieson
makes a sly cameo appearance in
the show. Framed on the wall in
his oﬃce is a photo of Jamieson
with another class of students
from earlier days. “For our fearless leader,” reads a sign next to
the photo.
—Kathleen Raven

»

A doctor’s love
affair with medicine
and literature

For Anna Reisman, M.D., it was a
summer novel that pointed her to
a career in medicine.
As a rising Yale senior and
English major with no thought
of becoming a doctor, she read
Thomas Mann’s classic 1924 novel
The Magic Mountain, a tale of
tuberculosis patients at a Swiss
sanatorium. Surprised by her
own fascination with the disease,
she went on to read physicianwriters Oliver Sacks, M.D.,
Richard Selzer, M.D., HS ’61, and
Lewis Thomas, M.D. Soon she

was a medical student at New
York University.
Now an associate professor of
internal medicine, Reisman (pronounced “Reeseman”) has maintained a connection to literature
that affects how she teaches and
practices medicine. In essays for
such publications as The Atlantic,
Slate, and The New York Times,
she has pointed out the problem with overly dapper doctors,
defended nurse practitioners who
want to practice primary care
without physician oversight, and
described her own reluctance to
set foot in a hospice for the first
time. (Its homey coziness surprised her.) She has even explored
the troubling ethics of writing
about patients.
With Lisa Sanders, M.D. ’97,
HS ’00, associate professor of
medicine and author of the
Diagnosis column in The New
York Times Magazine, she codirects the Yale Internal Medicine
Residency Writers’ Workshop. The
workshop guides residents as they
turn patient care experiences into
thoughtful narratives. Reisman
also directs the standardized
patient program through the
Teaching and Learning Center and
plays flute with a klezmer group,
the Nu Haven Kapelye, and the
Yale Medical Symphony Orchestra.
In March, Reisman became
the new director of the Yale
Program for Humanities in
Medicine, inheriting the post
from Thomas P. Duffy, M.D.
Duffy had led the program since
1999 upon the retirement of
founding director Howard Spiro,
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M.D., an English major, published
writer, and tireless advocate for
intertwining the humanities
and medicine. What began as a
lecture series has under Duffy’s
tenure added a Yale Medical
Symphony Orchestra and figure
drawing classes at the School of
Art. The idea is to provide what
Duffy calls “an opportunity to
frolic in all of those realms, to
keep alive that spirit” of passion
for the humanities during medical training. Reisman intends to
weave humanities right into the
medical curriculum, exposing
students to film, literature, and
visual arts that give the science a
human context. She also plans to
create a social media presence for
the 32-year-old program.
Lectures, poetry readings,
dancing, drawing, creative writing, open mics—all pleasant,
perhaps. But does reading a work
of literature (or pondering a
painting) really make students
better doctors?
“Of course it does!” Reisman
said. “You read a great novel and
you really empathize with the
characters, you get into their
heads, you see things from their
perspective. What better training to be a good doctor than to be
able to imagine what a patient is
going through!”
On the lookout for lecturers
and collaborators across the
university, Reisman is combing
places like the School of Drama,
the Whitney Humanities Center,
and the Yale Center for British
Art. “There’s so much stuff going
on!” she said.

Reisman has the right dispoSystem in West Haven (includsition for her work, said Geoffrey ing a four-year interlude of
Liu, M.D. ’15, who developed
house calls). The move brought
a reflective writing workshop
them closer to Reisman’s sister
for third-year medical students
Lisa, who had just been diagand worked with Reisman to
nosed with a glioblastoma.
train students to succeed him.
(Lisa Reisman’s memoir of surReisman, he said, combines an
viving that tumor, 5 Months
easygoing manner with “blunt10 Years 2 Hours, was published
ness and a kind of candor that
this spring; she recently delivI’ve really come to appreciate.”
ered a lecture as part of the
Born at Yale-New Haven
humanities program.)
Hospital and raised in Hamden,
People sometimes profess
Reisman earned her English
surprise when an English major
degree at Yale. She graduated
chooses a career in medicine.
from medical school in 1993,
But to Reisman, the connection
then did her residency in pribetween the two fields is obvimary care internal medicine at
ous. “More than anything else,
NYU Medical Center/Bellevue
medicine is about the human
Hospital, staying an extra year
condition—people, their lives
as chief resident. Then, she and
and experiences,” she said,
medical school classmate Cary
“and that’s what the humanities
Gross, M.D., professor of mediare about.”
cine, moved to Baltimore; they
—Jenny Blair
married in 1998 and returned to
Connecticut a year later.
Since then, Reisman has
worked in primary care for the
VA Connecticut Healthcare

A novel about tuberculosis patients sparked Anna
Reisman's interest in
medicine. She now leads
the Yale Program for the
Humanities in Medicine.
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question and answer

			 How Roy Herbst
became a media go-to
guy on immunotherapy
W HEN T HE A MER IC A N SOCIET Y OF CL IN IC A L ONCOLOGY

met in Chicago this spring, one of the hottest topics was the
promise of immunotherapy against cancer. And one of the
point men for the media was Roy S. Herbst, M.S. ’84, Ph.D.,
M.D., chief of medical oncology at Smilow Cancer Hospital,
associate director for translational research, and Ensign
Professor of Medicine, who appeared on CNN, Fox News,
and in newspapers from as far away as South Africa and the
United Kingdom. He has spent more than 20 years both in
the lab, studying the underlying science of cancer, and in
the clinic, bringing novel treatments to patients. He shares
his colleagues’ excitement about immunotherapy, which
harnesses the body’s immune system to fight tumors.

watch a short film about Roy Herbst
at youtube.com/YaleMedicine

46 yalemedicine.yale.edu

master’s degree in clinical invesEven as a student at New
tigation from the Harvard-MIT
Rochelle High School in New
clinical investigator training
York, Herbst was interested in
program. He then went on to the
science. “I knew that I wanted
M.D. Anderson Cancer Center,
to help people, and I always
thought of medicine as a career.” where he led the lung cancer
section for almost 10 years.
He came to Yale as an underFive years ago he returned
graduate, leaving in 1984 with
to the School of Medicine, where
both bachelor's and master’s
he had come as a Yale freshman
degrees summa cum laude.
to study biophysics and bioHe earned a Ph.D. from The
chemistry. “I studied molecular
Rockefeller University in 1990
and an M.D. from Cornell in 1991. biology and gave my master’s
thesis defense in the conferHe completed his residency at
ence room where we now have
Brigham and Women’s Hospital
(BWH) in Boston and fellowships our developmental therapeutics
seminar once a month,” he said.
in oncology and hematology at
“The blackboard looks exactly
Dana-Farber Cancer Hospital
the same.”
and BWH, and he received a

Q&A WITH

Roy
Herbst

Why did you choose to devote
your career to oncology?

checkpoint PDL1 and the

At Cornell and Rockefeller,

inhibitors that have changed

I was interested in science

the field. You have these

John Curtis

establishment of PD1/PDL1

tumors, and you would hope

and medicine, and cancer
seemed like an area where

What is your role at Yale?

that the immune system’s

you could bring science to

My primary goal is to make

T cells would recognize

ing tumors to understand

bear on difficult problems.

sure that medical oncol-

the tumor as foreign. But

what it is about those that

immunopathology, sequenc-

In my second year of med

ogy offers state-of-the-art

the tumor makes a protein,

respond versus those that

school, my mother devel-

care while building a grant-

PDL1, which camouflages

don’t respond. The tumor

oped breast cancer. I remem-

funded research program.

the tumor, making it invis-

can, unfortunately, learn

ber taking her slides to the

As the chief of medical

ible. The new therapies are

how to become resistant.

pathology group to confirm

oncology I lead an ever-

trying to knock down that

The immune system has

her diagnosis and exploring

expanding group of medical

PDL1. A lot of this work, by

memory; and hopefully,

treatment options with my

oncologists with a robust

the way, comes from the

as the tumor adapts, the

professors and mentor. This

clinical service. As the asso-

studies of Lieping Chen

immune system also adapts.

seemed like a natural area

ciate cancer center director

here at Yale. Patients with

In some cases this does not

for me because of the pathol-

for translational research,

lung cancer who previously

occur and hence we are
developing even more new

ogy, the science, and the new

my team and I are work-

would succumb to their dis-

therapies that were evolving.

ing to enhance and build

ease within a year are now

combinations among tar-

You could bring together the

a grants infrastructure to

alive at two, three years or

geted therapies, vaccines,

science and the caring for

do more to bring scientists

more. We are seeing tumors

and other immunotherapies.

into the study of cancer. We

shrink more than 20 percent

want to get more people

of the time in lung cancer,

Do you see yourself as a
clinician or a scientist?

working together on the

25 percent of the time in

How did you become one
of the public faces of ASCO?

common problem of how to

melanoma, and 15 percent

Our medical oncology sec-

I see myself as someone who is

better treat someone with

of the time in renal cancer.

tion, led by Mario Sznol,

looking to the lab for new ideas

an incurable cancer. There

These agents are benefit-

Harriet Kluger, and Scott

and new drugs, while serving

is so much expertise at Yale

ing people, but it’s not a

Gettinger, did some of the

on the front line of the clinical

in basic science and clini-

home run. Only 20 to 25

earliest immunotherapy

people all in one career.

translation. I want to develop

cal care, but the real trick

percent of patients benefit.

studies for cancer. I led one

drugs that are safer and more

is to get everyone working

We clearly have to do better,

of the earliest Phase 1 trials

effective for cancer patients by

together to combat human

and current work is aimed

in immunotherapy, which

understanding why they work

disease. My real goal is not

at identifying biomarkers of

was published in Nature last

or why they don’t work. Every

just the lung program. I

response and resistance so

year. Since my work has been

Tuesday I see patients at the

need to see every program

we can develop even more

focusing on both the clinic

Smilow hospital in the lung

in the cancer center succeed

effective combinations.

clinic, which I lead, and seek

in the same way.

and the science. I’m able to
talk not just about the clini-

What are the next steps?

to implement the most novel

cal results, but also about the

One of our big initiatives

science behind the results.

at Yale is to collect tumor

And what good is your work

we’re doing some basic trans-

Why has immunotherapy
emerged as such a breakthrough? What better than

samples from patients who

if you can’t make people real-

lational studies, but we mostly

the specificity, memory, and

have responded to immuno-

ize what you’re doing to help

collaborate with some of the

adaptability of one’s own

therapy and from those who

patients, to obtain grants, to

top labs at Yale and elsewhere.

immune system to attack a

have not. We are performing

encourage philanthropy and

protocol-driven care. I also
maintain a small lab where

TERRY DAGR ADI PHOTO

CONDUCTED BY

cancer? It really is the iden-

encourage other researchers

tification of the immune

to work with you?

{ To nominate a subject for Q&A, contact

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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book review
said ‘Jim wants to live out
on the street again,’ ” said
Rowe. Team members were
incredulous: why would Jim
want to return to the pavement under the Water Street

and Addiction Services, and

overpass? The outreach

the Melville Charitable Trust.

worker explained, “Because

They registered people to

there he knew people. He

vote; helped clients con-

felt that he belonged.” Rowe

nect with people who shared

recalled: “That was a heart-

their interests, such as fellow

breaking moment that

cycling enthusiasts or stock

revealed to me the limita-

traders; and encouraged

tions of what we were doing.”

clients to help others, for

led Rowe to launch what
would become the Citizens

		 A sense of
community for people
with mental illnesses
By Cathy Shufro

example, by serving on an
advisory board.
Citizenship, as the team

Collaborative. Its aim was to

came to define it, comprises

integrate people with mental

rights like freedom from

illness into communities

stigma, responsibilities like

beyond those created by the

knowing how to manage

mental health system. “Even

money, roles as parents or

the most innovative mental

employees, resources like

health programs, in which

housing and religious com-

work was more than work,

munities, and relationships

went beyond the clock, and

with others.

even smashed the damned
clock, could not make

A randomized controlled
study of 114 people who

people neighbors, commu-

received mental health ser-

nity members, and citizens,”

vices showed that those who

Rowe wrote. He envisioned

participated in a citizenship

people with mental illness

program were more satisfied

walking down streets to

with their lives and less apt

greetings from neighbors

to misuse alcohol and drugs.

Citizenship and Mental

worker who gradually won

and invitations to join in

Health began when a man

his trust, convinced him

a neighborhood clean-up

ship, said Rowe, is rooted in

This need to foster citizen-

who’d once been homeless

to get treatment for his ill-

or take part in discussions

the deinstitutionalization of

said that he wanted to give

ness, and helped him find

about upcoming elections.

the 1960s and “came out of

up his apartment and return

an apartment. “Jim was the

Rowe and colleagues

the success of mental health

to the streets of New Haven.

quintessential success story

created and studied citi-

outreach work—reaching its

of outreach,” said Rowe, an

zenship programs in New

limit and hitting the wall.” To

Michael Rowe, Ph.D. ’96, was

associate professor of psy-

Haven, funded by the

thrive, people with mental ill-

a veteran who heard voices.

chiatry and co-director of the

National Institute of Mental

ness need more than just ser-

He had initially resisted the

Yale Program for Recovery

Health, the Connecticut

vices, said Rowe. They need to

overtures of a peer outreach

and Community Health.

Department of Mental Health

“come in from the margins.”

Jim, said sociologist

And then, one day,
“his outreach worker came
into our team meeting and

{ Send notices of new books to

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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A guide for setting up citizenship
programs will be posted at medicine.yale.edu/psychiatry/prch/.

O P P O S I T E PA G E , J O H N C U R T I S P H O T O

That day in the mid-1990s

end note

The most cooperative of patients
T H I R D -Y E A R S T U D E N T S

beginning their clinical clerkships took to the new Yale Center for

Medical Simulation on June 15 to practice clinical skills best learned on a manikin instead
of a live patient. At the expanded center, which opened in January, they used bag-valve
masks for manual ventilation and inserted catheters and nasogastric tubes into the practice
manikins. “Our patients today are cooperative for you,” joked Leigh V. Evans, M.D.,
director of health care simulation. In addition to learning technical procedures, clerkship
students have the opportunity to lead medical teams in simulated case studies based on
real patients. “It’s active learning, it's feedback, and they get to practice,” said Evans.
—Karen Zusi

